(Q39902528)

15 September 2017

title

Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients (English)

1 reference

15 September 2017

0 references

1 reference

metastatic breast cancer

1 reference

Rachel E Payne

1

1 reference

15 September 2017

Ernesto Yagüe

2

1 reference

15 September 2017

Martin J Slade

3

1 reference

15 September 2017

Christos Apostolopoulos

4

1 reference

15 September 2017

Long R Jiao

5

1 reference

15 September 2017

Becky Ward

6

1 reference

15 September 2017

R Charles Coombes

7

1 reference

15 September 2017

Justin Stebbing

8

1 reference

15 September 2017

publication date

1 January 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

10

1 reference

15 September 2017

issue

1

1 reference

15 September 2017

page(s)

51-57

1 reference

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

HER-2 gene amplification can be acquired as breast cancer progresses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

REporting recommendations for tumor MARKer prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.51

21 January 2018

Identifiers

DOI

10.2217/14622416.10.1.51

1 reference

15 September 2017

1 reference